Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00346385
Other study ID # CDR0000491231
Secondary ID IMMUNO-C10/IVB/0
Status Completed
Phase Phase 1
First received June 28, 2006
Last updated March 24, 2015
Start date March 2002
Est. completion date October 2011

Study information

Verified date March 2015
Source ImmunoGen, Inc.
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

RATIONALE: Monoclonal antibodies, such as BB-10901, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.

PURPOSE: This phase I trial is studying the side effects and best dose of BB-10901 in treating patients with relapsed or refractory solid tumors.


Description:

OBJECTIVES:

Primary

- Determine the safety and tolerability of BB-10901

- Determine the maximum tolerated dose of this drug in these patients.

Secondary

- Determine the pharmacokinetics of this drug in these patients.

- Determine the efficacy of this drug in these patients.

OUTLINE: This is an open-label, multicenter, dose-escalation study.

Patients receive BB-10901 IV over 40 minutes once daily on days 1-3.* Treatment repeats every 21 days

NOTE: *Patients who do not tolerate 3 consecutive daily infusions of BB-10901 may receive infusions of BB-10901 on 3 alternate days, upon approval by the investigator and/or the independent Safety Review Board.

Cohorts of 4-6 patients receive escalating doses of BB-10901 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 4-6 patients experience dose-limiting toxicity in course 1. Up to 40 patients are treated at the MTD.

After completion of study treatment, patients are followed for short term and long term follow up and survival.

PROJECTED ACCRUAL: Approximately 100 patients will be accrued to this study.


Other known NCT identifiers
  • NCT00625287

Recruitment information / eligibility

Status Completed
Enrollment 97
Est. completion date October 2011
Est. primary completion date October 2011
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility DISEASE CHARACTERISTICS During Dose Escalation:

- Histologically or cytologically confirmed diagnosis of 1 of the following:

- Small cell lung cancer (SCLC)

- Other pulmonary tumors of neuroendocrine origin, including neuroendocrine carcinoma or non-SCLC with neuroendocrine features

- Non-pulmonary small cell carcinoma

- Metastatic carcinoid tumor

- Other CD56-positive solid tumor

- Diagnoses other than SCLC must have confirmation of tumor CD56 expression before study entry

- Relapsed or refractory disease

- Must have received at least 1 but no more than 3 prior chemotherapy regimens* and recovered from any acute toxicities

- No prior chemotherapy for carcinoid or neuroendocrine tumors

DISEASE CHARACTERISTICS During MTD Expansion:

- Relapsed or refractory Small cell lung cancer (SCLC)

- Metastatic Merkel Cell carcinomas

- Ovarian carcinomas

At the MTD:

SCLC patients must have received one, but no more than 1 prior chemotherapy regimen Merkel and Ovarian patients must have received at least one prior chemotherapy regimen. Ovarian patients must have received at least one platinum-based regimen.

- Measurable disease, defined as = 1 unidimensionally measurable lesion = 20 mm by conventional techniques or = 10 mm by spiral CT scan

- No uncontrolled carcinoid syndrome (e.g., flushing, uncontrolled diarrhea, labile blood pressure)

- No active brain metastases; no evidence of active disease and no requirement for anticonvulsant medications or steroids.

PATIENT CHARACTERISTICS:

- Life expectancy = 3 months

- ECOG performance status 0-2

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- Absolute neutrophil count = 1,500/mm^3

- Platelet count = 100,000/mm^3

- Hemoglobin = 10 g/dL

- Creatinine = 1.5 times upper limit of normal (ULN)

- AST and ALT = 2.5 times ULN

- Bilirubin = 3 times ULN

- No rapidly rising liver function tests (LFTs)

- Pancreatic function, amylase and lipase within upper limit of normal.

- No significant residual neurological or cardiac toxicity = grade 2 after prior chemotherapy

- No myocardial infarction within the past 6 months

- No unstable angina pectoris

- No uncontrolled congestive heart failure

- No uncontrolled arrhythmia

- No severe aortic stenosis

- No history of multiple sclerosis or other demyelinating disease

- No Eaton-Lambert syndrome (para-neoplastic syndrome)

- No history of hemorrhagic stroke

- No CNS injury with residual neurologic deficit

- No ischemic stroke within the past 6 months

- No history of pancreatitis

- No current active infection or history of recurrent infection with varicella-zoster virus (shingles) or cytomegalovirus

- No other concurrent serious infection

- No chronic alcoholism

- No other concurrent illness or condition that would interfere with study outcome

- No other malignancy within the past 3 years except adequately treated basal cell carcinoma of the skin or carcinoma in situ of the cervix

- No known recent biochemical or clinical evidence of pancreatitis or extensive metastatic disease involving the pancreas

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

- Total cumulative dosage of prior anthracycline treatment must not exceed threshold for cardiotoxicity

- No known hypersensitivity to previous monoclonal antibody therapy

- More than 4 weeks since prior and no concurrent chemotherapy or radiotherapy

- More than 4 weeks since prior and no other concurrent investigational agents

- At least 4 weeks since prior and no concurrent surgery

- No other concurrent antineoplastic treatment, including immunotherapy or steroid therapy

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
BB-10901
dose escalation study, dose will vary per cohort. patients will receive an IV infusion once every three weeks.

Locations

Country Name City State
United Kingdom Christie Hospital NHS Trust Manchester England
United Kingdom Cancer Research Centre at Weston Park Hospital Sheffield England
United Kingdom Royal Marsden NHS Foundation Trust - Surrey Sutton England
United States The Ohio State University Cancer Center and Research Institute Columbus Ohio
United States M. D. Anderson Cancer Center at University of Texas Houston Texas
United States Nevada Cancer Institute Las Vegas Nevada
United States Oklahoma University Oklahoma City Oklahoma
United States University of California San Francisco San Francisco California
United States Fred Hutchinson Cancer Research Center Seattle Washington

Sponsors (1)

Lead Sponsor Collaborator
ImmunoGen, Inc.

Countries where clinical trial is conducted

United States,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety and tolerability assessed by toxicity evaluation and prothrombin time assessments these tests will be conducted at various timepoints during a patients participation in the trial Yes
Secondary Pharmacokinetics assessed by measuring intact conjugate and total huN901 antibody concentration for each time point and dose level PK is assessed during the first cycle (21 days) of a patients participation No
Secondary Efficacy assessed by measuring response (complete or partial response) and biomarker levels of neuron-specific enolase and soluble neural cell adhesion molecules (NCAM) efficacy is assessed every 2 cycles during a patients participation while other blood tests are taken during every cycle No
See also
  Status Clinical Trial Phase
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Withdrawn NCT05201001 - APX005M in Patients With Recurrent Ovarian Cancer Phase 2
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Not yet recruiting NCT06376253 - A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers Phase 1
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT05156892 - Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer Phase 1
Suspended NCT02432378 - Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines Phase 1/Phase 2
Recruiting NCT04533763 - Living WELL: A Web-Based Program for Ovarian Cancer Survivors N/A
Active, not recruiting NCT03371693 - Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer Phase 3
Withdrawn NCT03032614 - Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients Phase 2
Completed NCT02019524 - Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients Phase 1
Completed NCT01936363 - Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer Phase 2
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT05059522 - Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing Phase 3
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Terminated NCT04586335 - Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Phase 1
Terminated NCT03146663 - NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer Phase 2